Overview

17OHP-C Dosing Among Obese Pregnant Women

Status:
Unknown status

Trial end date:
2020-08-23

Target enrollment:

Participant gender:

Summary

Emergency data suggest 17OHP-C may be less efficacious in obese women. Since obesity is associated with lower levels of plasma 17OHP-C, the investigator hypothesize that higher doses of 17OHP-C may help to prevent spontaneous PTB among obese women. The study aims to compare the pharmacokinetics of 17 OHP-C in obese compared with non-obese women.

Phase:

Phase 3

Details

Lead Sponsor:

University of South Florida

Collaborator:

Washington University School of Medicine

Treatments:

11-hydroxyprogesterone
17 alpha-Hydroxyprogesterone Caproate
17-alpha-hydroxy-progesterone caproate